Stockwatch: Murky waters run deep
This article was originally published in Scrip
The seasons of quarterly and annual results come and go, but as the perpetual and slavish cycle of public disclosure continues, the opportunities for information subterfuge and concealment of bad news expand. In our interconnected and instantaneously updated world, information is copious and cheap, but enlightenment is rather more difficult to acquire. Just as the desert and the ocean are both hostile environments for a thirsty mammal, so secrecy and information overload are both enemies of transparency.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.